BlueCross BlueShield of Western New York and Roswell Park Comprehensive Cancer Center announced Sunday that a contract has been reached to continue coverage at Roswell for BlueCross BlueShield customers through 2022.
“We are thrilled that we can count on BlueCross BlueShield of Western New York to cover one of our region’s most vulnerable patient populations,” said Candace S. Johnson, PhD, president and CEO of Roswell Park Comprehensive Cancer Center said in a press release.
Roswell Park is a recognized Blue Distinction Center, through the BlueCross BlueShield Association, for their quality and the cost of Cancer Care, Blood and Marrow Transplants, and Cellular Immunotherapy, also known as CAR-T.
“Access to high-quality, comprehensive care is so important for people with cancer,” Johnson added in the release. “We are happy to work together so that we can continue to offer our patients the latest and most promising therapies.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
In Buffalo, Roswell is currently the only center that can provide Kymriah and Yescarta, two cancer therapies that use modified versions of the patient’s immune cells.
“The ‘long game’ for a provider such as Roswell is to identify the most effective treatments that minimize the impact of a cancer diagnosis,” said David W. Anderson, president and CEO of BlueCross BlueShield of Western New York in the press release. “When we work collaboratively, we have a meaningful impact on the health of our community.”